Active substance
Zolmitriptan
- US FDA 26
- Health Canada 16
- US price lines 7
- NHS prices 7
- Safety 3
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZOMIG | 2.5MG/SPRAY; 5MG/SPRAY | spray · nasal | AMNEAL | Prescription | 30 Sep 2003 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 14 May 2013 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet, orally disintegrating · oral | GLENMARK PHARMS LTD | Prescription | 14 May 2013 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet, orally disintegrating · oral | ZYDUS PHARMS USA INC | Prescription | 15 May 2013 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | JUBILANT GENERICS | Prescription | 20 Nov 2014 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet, orally disintegrating · oral | JUBILANT GENERICS | Prescription | 17 Sep 2015 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | ALEMBIC | Prescription | 30 Sep 2015 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | AUROBINDO PHARMA | Prescription | 11 May 2016 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | AJANTA PHARMA LTD | Prescription | 20 May 2016 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet, orally disintegrating · oral | ALEMBIC | Prescription | 1 Dec 2016 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | PLD ACQUISITIONS LLC | Prescription | 27 Feb 2017 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | CHARTWELL RX | Prescription | 30 Jun 2017 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | ZYDUS PHARMS | Prescription | 11 Jul 2018 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | ORBION PHARMS | Prescription | 21 Oct 2019 |
| ZOLMITRIPTAN | 2.5MG/SPRAY; 5MG/SPRAY | spray · nasal | PADAGIS ISRAEL | Prescription | 30 Sep 2021 |
| ZOMIG | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | IPR | Discontinued | 25 Nov 1997 |
| ZOMIG-ZMT | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, orally disintegrating · oral | ASTRAZENECA | Discontinued | 13 Feb 2001 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | APOTEX INC | Discontinued | 14 May 2013 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet, orally disintegrating · oral | APOTEX INC | Discontinued | 14 May 2013 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | NATCO PHARMA USA | Discontinued | 14 May 2013 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | ANI PHARMS | Discontinued | 4 Mar 2014 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | INVAGEN PHARMS | Discontinued | 9 Apr 2014 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | SUN PHARMA GLOBAL | Discontinued | 13 Nov 2014 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet · oral | MACLEODS PHARMS | Discontinued | 30 Sep 2015 |
| ZOLMITRIPTAN | 2.5MG; 5MG | tablet, orally disintegrating · oral | MACLEODS PHARMS | Discontinued | 22 Oct 2015 |
1 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-ZOLMITRIPTAN | 02481030 | 2.5 MG | TABLET · ORAL | AURO PHARMA INC |
| BIO-ZOLMITRIPTAN | 02512831 | 2.5 MG | TABLET · ORAL | BIOMED PHARMA |
| JAMP-ZOLMITRIPTAN | 02421623 | 2.5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| M-ZOLMITRIPTAN | 02566133 | 2.5 MG | TABLET · ORAL | MANTRA PHARMA INC |
| MAR-ZOLMITRIPTAN | 02399458 | 2.5 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MINT-ZOLMITRIPTAN | 02419521 | 2.5 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| NAT-ZOLMITRIPTAN | 02421534 | 2.5 MG | TABLET · ORAL | NATCO PHARMA (CANADA) INC |
| NRA-ZOLMITRIPTAN | 02489392 | 2.5 MG | TABLET · ORAL | NORA PHARMA INC |
| SANDOZ ZOLMITRIPTAN | 02362988 | 2.5 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ ZOLMITRIPTAN ODT | 02362996 | 2.5 MG | TABLET (ORALLY-DISINTEGRATING) · ORAL | SANDOZ CANADA INCORPORATED |
| TEVA-ZOLMITRIPTAN | 02313960 | 2.5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-ZOLMITRIPTAN OD | 02342545 | 2.5 MG | TABLET (ORALLY-DISINTEGRATING) · ORAL | TEVA CANADA LIMITED |
| ZOMIG | 02238660 | 2.5 MG | TABLET · ORAL | XEDITON PHARMACEUTICALS INC |
| ZOMIG NASAL SPRAY | 02248992 | 2.5 MG / ACT | SPRAY · NASAL; ORAL | XEDITON PHARMACEUTICALS INC |
| ZOMIG NASAL SPRAY | 02248993 | 5 MG / ACT | SPRAY · ORAL; NASAL | XEDITON PHARMACEUTICALS INC |
| ZOMIG RAPIMELT | 02243045 | 2.5 MG | TABLET (ORALLY-DISINTEGRATING) · ORAL | XEDITON PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ZOLMITRIPTAN 2.5 MG ODT | $2.06825 | per EA | 23 Sep 2026 |
| US NADAC | ZOLMITRIPTAN 2.5 MG TABLET | $1.0228 | per EA | 23 Sep 2026 |
| US NADAC | ZOLMITRIPTAN 5 MG NASAL SPRAY | $44.03928 | per EA | 23 Sep 2026 |
| US NADAC | ZOLMITRIPTAN 5 MG ODT | $3.24791 | per EA | 23 Sep 2026 |
| US NADAC | ZOLMITRIPTAN 5 MG TABLET | $1.35334 | per EA | 23 Sep 2026 |
| US NADAC | ZOMIG 2.5 MG NASAL SPRAY | $108.56466 | per EA | 18 Feb 2026 |
| US NADAC | ZOMIG 5 MG NASAL SPRAY | $108.8863 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Zolmitriptan 2.5mg orodispersible tablets sugar free | £3.07 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Zolmitriptan 2.5mg tablets | £30.43 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Zolmitriptan 2.5mg tablets | £60.87 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Zolmitriptan 5mg orodispersible tablets sugar free | £3.63 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Zolmitriptan 5mg tablets | £36.00 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Zolmitriptan 5mg tablets | £72.00 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Zolmitriptan 5mg/0.1ml nasal spray unit dose | £42.47 | 6 unit dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 21 Dec 2018 ZOMIG — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Dec 2018 ZOMIG — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Dec 2018 ZOMIG-ZMT — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.